WebDoctor Encyclopedia

Article

Bevacizumab

What is bevacizumab?

Bevacizumab is a targeted cancer medicine made from an antibody. It works by cutting off the blood supply that tumours need to grow. It is given as a drip into a vein, usually every 2 or 3 weeks, and is almost always combined with chemotherapy or other cancer treatments.

Tumours need a blood supply to bring them oxygen and nutrients. To get one, they release a signalling protein called VEGF (vascular endothelial growth factor), which encourages new blood vessels to grow towards them. Bevacizumab attaches to VEGF and blocks it. This is known as anti-angiogenic treatment, because it targets angiogenesis, the growth of new blood vessels.

Bevacizumab is used for several cancers, including bowel cancer, lung cancer, ovarian cancer, cervical cancer, liver cancer and some brain tumours. The original brand is Avastin, and several biosimilar versions are now available. Biosimilars are medicines that work in the same way and have been shown to be equally effective.

A brief history

In 1971, the American surgeon Judah Folkman proposed that tumours depend on new blood vessels and that blocking them could be a new way to treat cancer. VEGF was identified in the late 1980s. Bevacizumab, a humanised antibody against VEGF, was developed in the 1990s. In 2004, it became the first anti-angiogenic medicine to be approved, after a trial in advanced bowel cancer showed that it helped people live longer when added to chemotherapy (Hurwitz et al., 2004).

1. Key facts at a glance

Feature Details
Type of treatment Targeted therapy (monoclonal antibody)
Target VEGF, a protein that drives new blood vessel growth
Main uses Bowel, lung, ovarian, cervical and liver cancers; recurrent glioblastoma
How it is given Drip into a vein over 30-90 minutes
Schedule Every 2 or 3 weeks
Usually combined with Chemotherapy, immunotherapy or other targeted drugs
Main side effects High blood pressure, protein in urine, nosebleeds, slow wound healing, blood clots, rarely bowel perforation

Before deciding

Because the benefit of bevacizumab varies between cancers and between people, it is worth asking your team how much difference they expect it to make in your situation. For some people, the extra visits and side effects are well worth it; for others, chemotherapy alone may be a reasonable choice.

2. How it works

Starving the tumour

Step What happens
1. Tumour releases VEGF Signals for new blood vessels
2. Bevacizumab binds VEGF VEGF can no longer attach to blood vessel cells
3. New vessel growth slows The tumour’s blood supply is reduced
4. Existing vessels become more normal Chemotherapy may reach the tumour better

Why it is combined with other treatments

On its own, bevacizumab has limited effect on most cancers. It works best alongside chemotherapy or other drugs. One theory is that it makes the chaotic blood vessels in tumours more orderly for a while, helping chemotherapy reach the cancer cells.

Why it affects healthy tissues

VEGF also helps maintain healthy blood vessels, keep the kidney filters working and heal wounds. Blocking it explains many of bevacizumab’s side effects, such as high blood pressure, protein leaking into urine and slow wound healing.

3. Who it is for

Conditions treated

Condition Role of bevacizumab
Colorectal adenocarcinoma With chemotherapy for advanced bowel cancer
Non-small cell lung cancer With chemotherapy, and sometimes immunotherapy, for advanced non-squamous cancer
High-grade serous ovarian carcinoma With chemotherapy and as maintenance, sometimes with a PARP inhibitor
Cervical cancer With chemotherapy for advanced or recurrent disease
Hepatocellular carcinoma With the immunotherapy atezolizumab for advanced liver cancer
Glioblastoma For recurrent tumours in some countries, mainly to reduce swelling
Clear cell renal cell carcinoma Occasionally, with other drugs

How bevacizumab is used in different cancers

In advanced bowel cancer, bevacizumab is commonly added to chemotherapy combinations such as FOLFOX, FOLFIRI or capecitabine-based treatment. It may be continued with a lighter chemotherapy as maintenance once the cancer is under control. It is not used after surgery for early bowel cancer, because trials did not show a benefit in that setting.

In ovarian cancer, it is given with carboplatin and paclitaxel after surgery and then continued on its own, or with the PARP inhibitor olaparib for some women, as maintenance treatment.

In liver cancer, bevacizumab is combined with the immunotherapy drug atezolizumab as a first treatment for advanced disease. Before starting, people usually have an endoscopy to look for and treat swollen veins in the gullet, because of the bleeding risk.

In glioblastoma that has come back, bevacizumab can reduce swelling around the tumour, which may ease symptoms and allow steroid doses to be lowered, although it has not been shown to help people live longer.

Who should be careful

Situation Reason
Recent or planned major surgery Bevacizumab slows wound healing
Recent serious bleeding It can increase bleeding risk
Recent heart attack or stroke Higher risk of blood clots
Uncontrolled high blood pressure It can raise blood pressure further
Squamous lung cancer Higher risk of bleeding from the lung; generally not used
Pregnancy It can harm an unborn baby

4. Before treatment

Step Why it is done
Blood pressure check Baseline before treatment
Urine test Checks for protein
Blood tests Blood counts, kidney and liver function
Surgery timing Bevacizumab is usually stopped several weeks before planned surgery and restarted when wounds have healed
Medicines review Including blood thinners and blood pressure medicines
Dental review Avoid dental extractions during treatment if possible

5. What to expect: step by step

Step What happens
1. Blood pressure and urine check Before each dose
2. Blood tests As needed for the chemotherapy being given
3. Drip First dose over about 90 minutes; later doses can be faster
4. Other treatments Chemotherapy or other drugs given on the same day
5. Home Usually the same day
6. Repeat Every 2 or 3 weeks

How long treatment lasts

In advanced cancer, bevacizumab is often continued as long as it is helping and side effects are manageable. In ovarian cancer after surgery, it is usually given for about a year or more as maintenance.

6. Side effects and risks

Common side effects

Side effect What to expect
High blood pressure Common; checked at every visit and treated with medicines
Protein in urine Usually without symptoms; checked with urine tests
Nosebleeds Usually minor
Tiredness Common, especially with chemotherapy
Headache Sometimes related to blood pressure
Slow wound healing Planned around surgery
Voice changes Hoarseness sometimes

Serious but uncommon risks

Risk What to look for
Bowel perforation Severe tummy pain, vomiting or fever; needs emergency care
Fistula An abnormal connection between organs
Serious bleeding Coughing or vomiting blood, black stools
Blood clots Leg swelling, chest pain or sudden breathlessness
Heart attack or stroke Chest pain, sudden weakness or speech problems
Severe high blood pressure Severe headache, confusion or vision changes
Jaw bone problems Rarely, especially with bone-strengthening drugs

How often do these happen?

In the bowel cancer trial that led to approval, severe high blood pressure occurred in 11% of people given bevacizumab compared with 2.3% without it (Hurwitz et al., 2004). In the lung cancer trial, significant bleeding occurred in 4.4% of those receiving bevacizumab, compared with 0.7% without (Sandler et al., 2006). In cervical cancer, gastrointestinal fistulas occurred in 3% (Tewari et al., 2014).

7. Results and outlook

Study Main finding
Advanced bowel cancer, first-line Adding bevacizumab to chemotherapy improved median survival from 15.6 to 20.3 months (Hurwitz et al., 2004)
Advanced non-squamous lung cancer Median survival was 12.3 months with bevacizumab and chemotherapy versus 10.3 months with chemotherapy alone (Sandler et al., 2006)
Advanced cervical cancer (GOG 240) Median survival improved from 13.3 to 17.0 months (Tewari et al., 2014)
Ovarian cancer after surgery (GOG-0218), 1,873 women Continuing bevacizumab as maintenance lengthened progression-free survival from 10.3 to 14.1 months (Burger et al., 2011)

What the results mean

Bevacizumab adds a modest but real benefit to chemotherapy in several cancers. It can help shrink tumours, delay growth and, in some cancers, extend life by a few months. The size of the benefit varies, and it must be balanced against side effects.

8. Recovery and aftercare

Tip Why
Check blood pressure as advised Some people monitor it at home
Take blood pressure medicines regularly If prescribed
Report severe tummy pain urgently Could signal perforation
Tell any surgeon or dentist Treatment may need pausing before procedures
Report leg swelling or breathlessness Possible blood clot
Avoid heavy blowing of the nose Helps reduce nosebleeds

Nosebleeds

Minor nosebleeds are common. Sitting up, leaning forward and pinching the soft part of the nose for 10-15 minutes usually stops them. Seek help if bleeding is heavy or does not stop.

Managing high blood pressure

Some teams ask you to check your blood pressure at home with an automatic monitor, especially in the first few months. Keep a record and bring it to appointments. Reducing salt, staying active and taking any prescribed medicines regularly all help. If your blood pressure becomes very high, bevacizumab may be paused until it is controlled.

Protein in the urine

Small amounts of protein in the urine are common and usually cause no symptoms. If the level rises, a 24-hour urine collection or a blood and urine ratio test may be arranged, and treatment may be paused until it improves.

Follow-up

Blood pressure and urine protein are checked before each dose. Scans are done at regular intervals to see how the cancer is responding.

Biosimilars

Many hospitals now use biosimilar versions of bevacizumab. These are made by different manufacturers, are tested to show that they work in the same way, and are usually less expensive. You may notice a different name on your treatment chart, but the treatment itself is the same.

Coping with treatment

Living with advanced cancer and ongoing treatment can be tiring and stressful. Plan regular rest, keep gently active and accept help from friends and family. Specialist nurses, counsellors and support groups can help you cope with the emotional side of treatment.

9. Alternatives

Alternative When it is considered
Chemotherapy alone When bevacizumab is unsuitable or of little expected benefit
Other anti-angiogenic drugs Such as ramucirumab, aflibercept or tablet drugs that block VEGF receptors
Immune checkpoint inhibitors Lung, liver, cervical and other cancers
PARP inhibitors Maintenance in ovarian cancer, sometimes with bevacizumab
EGFR inhibitors Lung cancer with EGFR mutations
TACE and radioembolisation (SIRT) Liver cancer confined to the liver

10. Frequently asked questions

Question Answer
Is bevacizumab chemotherapy? No, it is a targeted antibody, but it is usually given with chemotherapy
Will I lose my hair? Not from bevacizumab itself; chemotherapy may cause hair loss
What is a biosimilar? A version made by another company that works the same way
Can I have surgery during treatment? Usually only after pausing bevacizumab for several weeks
Can I take aspirin? Ask your team; it may increase bleeding risk
How long will I have it? As long as it helps in advanced cancer; set periods in some cases
Can I exercise? Yes, gentle to moderate exercise is encouraged
Can I travel? Usually, between treatments; take your blood pressure medicines with you
Will my blood pressure return to normal? Usually, after treatment stops

11. Questions to ask your care team

  • What benefit do you expect bevacizumab to add for me?
  • Which other treatments will I have with it?
  • How will my blood pressure and urine be monitored?
  • What should I do before any surgery or dental work?
  • Which symptoms need urgent attention?
  • How long will treatment last?

Resources

  1. Burger, R.A. et al. (2011) ‘Incorporation of bevacizumab in the primary treatment of ovarian cancer’, New England Journal of Medicine, 365(26), pp. 2473-2483.
  2. Hurwitz, H. et al. (2004) ‘Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer’, New England Journal of Medicine, 350(23), pp. 2335-2342.
  3. Sandler, A. et al. (2006) ‘Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer’, New England Journal of Medicine, 355(24), pp. 2542-2550.
  4. Tewari, K.S. et al. (2014) ‘Improved survival with bevacizumab in advanced cervical cancer’, New England Journal of Medicine, 370(8), pp. 734-743.
  5. National Cancer Institute (2026) Bevacizumab. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/bevacizumab (Accessed: October 2026).

Prepared by the editorial team, October 2026.